Lundbeck Q3 2019 Financial Results

Solid volume growth in the U.S. for all strategic brands 100.000 75.000 50.000 25.000 NEW +17% Abilify Maintena +21% 800.000 0 Q3.17 300.000 REXULTI +31% 200.000 100.000 54 54 Q3.18 0 Q3.17 Q3.18 +22% Trintellix vortioxetine +22% 5mg-10mg 20mg tablets +24% 600.000 400.000 200.000 0 Q3.19 Q3.19 Northera™ 12.000 (droxidopa) capsules 100mg-200mg-300ng 9.000 6.000 3.000 0 Source: Symphony Health (ref Bloomberg) Q3.17 -14% Q3.18 Q3.19 +18% Q3.17 Q3.18 Lundbeck Q3.19

View entire presentation